Dengue: a continuing global threat

The Human Immune Response to Dengue Virus Is Dominated by Highly Cross-Reactive Antibodies Endowed with Neutralizing and Enhancing Activity

(2010) Martina Beltramello et al.   Cell Host & Microbe

A Novel Tetravalent Dengue Vaccine Is Well Tolerated and Immunogenic against All 4 Serotypes inFlavivirus‐Naive Adults

(2010) Dennis Morrison et al.   JOURNAL OF INFECTIOUS DISEASES

Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans

(2010) W. Dejnirattisai et al.   SCIENCE

Phase 1 Trial of the Dengue Virus Type 4 Vaccine Candidate rDEN4Δ30-4995 in Healthy Adult Volunteers

(2009) Peter F. Wright et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Dengue Plaque Reduction Neutralization Test (PRNT) in Primary and Secondary Dengue Virus Infections: How Alterations in Assay Conditions Impact Performance

(2009) Stephen J. Thomas et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses

(2008) John T. Roehrig et al.   VIRAL IMMUNOLOGY

Dengue Virus–Mosquito Interactions

(2007) Scott B. Halstead   Annual Review of Entomology